NCT01916109View on ClinicalTrials.gov

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

July 31, 2015

Conditions
Bladder Cancer
Interventions
DRUG

Gemcitabine

DRUG

Carboplatin

DRUG

Panitumumab

PROCEDURE

radical cystectomy

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memoral Sloan Kettering Cancer Center, Basking Ridge

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01916109 - Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter